Navigation Links
MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
Date:11/7/2007

Agreement Provides Additional Financial Flexibility to Ongoing Strategic

Exploration Process

GERMANTOWN, Md., Nov. 7 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, announced an agreement with Deerfield Management, a healthcare investment fund and one of the Company's largest equity shareholders, raising up to $10 million in cash.

Under the terms of the agreement, $7.5 million will be immediately received by the Company with an additional $2.5 million to become available, if necessary, if and when the Company receives U.S. Food and Drug Administration (FDA) approval of Amoxicillin PULSYS. The agreement is designed to provide the Company with the financial flexibility to continue its ongoing strategic discussions beyond the PDUFA date for Amoxicillin PULSYS. The cash provided from the Deerfield agreement will also allow MiddleBrook to repay in full its outstanding loan facility with Merrill Lynch and eliminate the associated interest and principal payments.

"We are pleased to enter into this agreement with Deerfield as it provides us with the financial flexibility to continue our strategic discussions beyond the Amoxicillin PULSYS PDUFA date," commented Dr. Edward Rudnic, MiddleBrook president and CEO. "This agreement will also allow us to repay our loan facility with Merrill Lynch which has restricted our use of cash and other corporate assets."

MiddleBrook also announced that its process to explore strategic alternatives is still ongoing and may extend beyond the Company's expected Amoxicillin PULSYS FDA action date of January 23, 2008. Midd
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Spector has joined the company as the new Global Communications Director for InHealth ... public relations experience having spent the last 16 years doing on-air television, producing ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert agrees ... and InHealth media is a global sales and communications firm that offers U.S. brands ... continue our business relationship with Mr. Reid Eckert, as his interpretation of the nutritional ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ... the expansion of global cosmeceutical and skin care brands. Mr. Fernandez comes ... last 25 years working in operations, purchasing and management for some of the ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional ... from Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products ... focused on your goals. Kathleen graduated from Florida State University with a ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:NPI Appoints New Executive Assistant To CEO 2
... , FRIDAY, Dec. 30 (HealthDay News) -- ... and skaters should take simple safety precautions, orthopedic experts ... that in 2010 more than 440,000 people were treated ... among snowboarders and skiers. These two sports accounted for ...
... Two recent studies by Van Andel Research Institute scientists ... distinct kidney cancer subtypes, which could pave the way for ... Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, ... of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive ...
... Dennis Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... was 19 years old. Then a sophomore studying physics at ... and depression for years. He said he,d self-medicated by drinking and ... demons that had been gnawing at his soul for years burst ...
... 2011 revision of the International Standards for the Neurological ... the November 2011 issue of the Journal of ... Steven Kirshblum et al clarifies the modifications to this ... http://www.ingentaconnect.com/content/maney/scm (#6, Nov 2011). ISNCSCI ...
... -- A new review of existing research suggests that, despite ... heart patients should get Plavix, a blood-thinning drug used to ... clopidogrel, is used to treat or prevent blood clots due ... as balloon angioplasty. But some patients ...
... Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. 28 ... are typically thought to be diseases of young women and ... drive a young person to an eating disorder may linger ... are coming forward to receive treatment for eating problems that ...
Cached Medicine News:Health News:Tips to Keep Winter Sports Injury-Free 2Health News:Tips to Keep Winter Sports Injury-Free 3Health News:Van Andel Research Institute findings provide more complete picture of kidney cancer 2Health News:Virginia Man Won't Let His Mental Illness Define Him 2Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Doubt Cast on Use of Genetic Test Before Plavix 2Health News:Eating Disorders Can Last Well Beyond Teen Years 2Health News:Eating Disorders Can Last Well Beyond Teen Years 3
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ("Perrigo") ... has completed the acquisition of leading OTC brands from ... million. The transaction is a clear demonstration of Perrigo,s ... leading European distribution network spanning 36 countries.  ... Papa commented, "We are excited to complete this ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
(Date:8/27/2015)... ALEXANDRIA, Va. , Aug. 27, 2015 /PRNewswire-USNewswire/ ... in the Food and Drug Administration,s (FDA,s) draft ... including reference products and biosimilars, to bear a ... years, AMCP has been seeking a decision from ... joined 18 diverse health care stakeholders urging the ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Castroviejo tying forceps, straight....
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures....
Medicine Products: